Italian Enthera Pharma raise 35m in Series A extension
Enthera Pharmaceuticals extends its 28m Series A financing from last July to a total of 35m as Roche Venture Fund joins the companys investor syndicate.
Enthera Pharmaceuticals extends its 28m Series A financing from last July to a total of 35m as Roche Venture Fund joins the companys investor syndicate.
A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Israels Omnix Medical has been granted 10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.
Germany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.
French Servier SA and the UKs MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
Irish life sciences company Neurent Medical has closed a 21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
J&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.
German Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.
European life sciences investors LSP has closed a new fund to fight dementia at 50m.
French Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.